The Health Innovation and Transformation Partnership, a ground-breaking collaboration between the NHS and academic and industry partners, has been extended for another three years.
Set up in 2022, the partnership is a collaboration between NHS Golden Jubilee’s national Centre for Sustainable Delivery, NHS Greater Glasgow & Clyde, University of Glasgow, AstraZeneca UK and Lenus Health.
The aim is to create transformation in NHS Scotland within both scheduled and unscheduled care through large scale programmes to improve the health of the population and by expanding clinical research.
Interventions will use a variety of novel approaches and technologies focusing upon wide-ranging points in the patient journey and pathways of care and will span early upstream detection, diagnosis and risk-stratification through to chronic disease management.
Some of the projects already underway as part of the Health Innovation and Transformation Partnership include:
- Optimised Pathway for Early Identification of Heart Failure in the Community (OPERA) – a collaboration between AstraZeneca UK, NHS Greater Glasgow & Clyde, University of Glasgow, Lenus Health and West of Scotland Innovation teams.
- Prevention of Chronic Obstructive Pulmonary Disease (COPD) Lung Attacks by early Intervention Strategies (POLARIS)
- Screening for early heart failure diagnosis and Management in Primary care or at Home using Natriuretic peptides and echocardiography (SYMPHONY) – a five-country trial with a Scottish arm called TARTAN-HF)
- Real world implementation of a supported treatment algorithm to shorten time to treatment in patients admitted with anticoagulation associated major bleeding (RECALL)
Dame Anna Dominiczak, the Scottish Government’s Chief Scientist for Health, said:
“The Health Innovation and Transformation Partnership will help provide unique opportunities to improve patient care, employ new technologies and medicines, while addressing the impact of health inequalities and social barriers to provide a more sustainable future healthcare system.
“The organisations involved in this partnership will bring their individual strengths in this fusion of medical expertise, knowledge and insight focused on innovation to deliver optimal patient outcomes and experiences.”
The Health Innovation and Transformation Partnership, set up in 2022, is a collaboration between NHS Golden Jubilee’s national Centre for Sustainable Delivery, NHS Greater Glasgow & Clyde, University of Glasgow, AstraZeneca UK and Lenus Health.
Centre for Sustainable Delivery
The national Centre for Sustainable Delivery is a national unit designed to sustainably improve and transform Scotland’s health care system through innovation, collaboration and clinical leadership. Hosted by NHS Golden Jubilee and commissioned by the Scottish Government, CfSD brings together existing transformation programmes with an innovation team to support the rapid rollout of new techniques, innovations and clinically safe, fast and efficient pathways for Scotland’s patients. CfSD will work with experts and patients across Scotland to make our healthcare system the best in the world and ensure that people receive the right care, from the right people, at the right time. To achieve this we need to focus on sustainability, value, innovation and listening to our patients.
NHS Golden Jubilee
A national institution, independently run by its own NHS Board, NHS Golden Jubilee delivers care through collaboration. NHS Golden Jubilee has a national portfolio and the Chief Executive is accountable for the Golden Jubilee University National Hospital, NHS Scotland Academy, the Centre for Sustainable Delivery, Golden Jubilee Research Institute and the Golden Jubilee Conference Hotel. The NHS National Waiting Times Centre continues to be the legal name for the Board.
NHS Greater Glasgow and Clyde
NHS Greater Glasgow and Clyde (NHSGGC) is the largest NHS organisation in Scotland and one of the largest in the UK, employing around 39,000 staff. NHSGGC is responsible for providing and managing a whole range of health services including hospitals and General Practice. Serving a population of 1.14million people, NHSGGC works alongside partnership organisations including Local Authorities and the voluntary sector.
About the University of Glasgow
Founded in 1451, The University of Glasgow is a world-class university, committed to working with global partners to create high-quality research with real-life impact. We were named the Scottish University of the Year by the Times & Sunday Times Good University Guide 2024 and have been home to world-changing research and teaching for more than 570 years. Our research excellence responds to some of the world’s greatest challenges in areas such as precision medicine and chronic diseases, one health, future life, addressing inequalities, cultural and creative economies, and the nano and quantum world. For more information, visit www.gla.ac.uk
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide. With a proud 100-year heritage in advancing UK science, today AstraZeneca is the UK’s leading biopharmaceutical company. The company is based in five different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,700 employees work in research and development, manufacturing, supply, sales, and marketing. We supply around 36 different medicines to the NHS.
For more information, please visit www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK.
About Lenus Health
Lenus Health focuses on deployment of digital tools and AI to health systems to transform the diagnosis and management of patients with chronic conditions. Our objectives are to deliver service efficiencies, support the delivery of guideline directed medical therapy and improve patient health outcomes. Lenus AI driven risk stratification models are live and in use within clinical workflows and help care teams identify at risk patients and support early interventions. Our digital tools help automate clinical workflows for a range of diagnostic pathways and enable remote monitoring and virtual wards solutions for managing high risk patients.
Learn more by visiting www.lenushealth.com and follow @lenushealth on X or LinkedIn.